Caption Management’s Taysha Gene Therapies TSHA Stock Holding History

Caption Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-490,700	Closed	-$2.7M	–	2077
2025 Q4	$2.7M	Buy	+490,700	New	+$2.38M	0.02%	729

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caption Management's TSHA Position: Q2 2022 in Review

Caption Management sold out of Taysha Gene Therapies (TSHA) in Q2 2022, closing a stake of 18,191 shares — an estimated $119K sold.

Caption Management first reported a position in TSHA in Q1 2022 and held it in 1 quarter. The position peaked at $119K in Q1 2022. 59 funds tracked by Wall St. Rank hold TSHA as of Q2 2022.

Caption Management reported no remaining Taysha Gene Therapies position as of Q2 2022 after selling out during the quarter.
Caption Management sold 18,191 Taysha Gene Therapies shares in Q2 2022, an estimated $119K.
Caption Management first reported a position in Taysha Gene Therapies in Q1 2022 and held it in 1 quarter.
Caption Management's Taysha Gene Therapies position peaked at $119K in Q1 2022.
59 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2022.

Based on Caption Management's 13F filing for Q2 2022, filed 15 Aug 2022.